Phaseline

Targets › PHOX2B

PHOX2B (Paired mesoderm homeobox protein 2B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jun 2032.

Involved in the development of several major noradrenergic neuron populations, including the locus coeruleus. Transcription factor which could determine a neurotransmitter phenotype in vertebrates. (UniProt, Q99453)

Open in Phaseline: the race on PHOX2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stephan Grupp MD PhDPHOX2B PC-CAR T Cells
PHOX2B-targeting chimeric antigen receptor (CAR) T cell therapy
PHOX2BPhase 1Refractory NeuroblastomaJun 2032

Conditions

Refractory Neuroblastoma (1)

Modalities

other (1)

Companies

Stephan Grupp MD PhD (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.